Bellerophon Therapeutics (Bellerophon Therapeutics) Total Current Assets : $4.98 Mil (As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Bellerophon Therapeutics Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Bellerophon Therapeutics's total current assets for the quarter that ended in Sep. 2023 was $4.98 Mil.

Bellerophon Therapeutics Total Current Assets Historical Data

The historical data trend for Bellerophon Therapeutics's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bellerophon Therapeutics Total Current Assets Chart

Bellerophon Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Current Assets

Get a 7-Day Free Trial

17.40

10.38

48.08

25.46

7.56

Bellerophon Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Total Current Assets	Get a 7-Day Free Trial															12.06	7.56	15.77	11.25	4.98

Bellerophon Therapeutics Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Bellerophon Therapeutics's Total Current Assets for the fiscal year that ended in Dec. 2022 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	6.924	+	0	+	0	+	0.639
	=	7.56

Bellerophon Therapeutics's Total Current Assets for the quarter that ended in Sep. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	4.382	+	0	+	0	+	0.597
	=	4.98

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Bellerophon Therapeutics (OTCPK:BLPH) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Bellerophon Therapeutics's Liquidation Value for the quarter that ended in Sep. 2023 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	4.382	-	1.256	+	0.75 * 0	+	0.5 * 0
=	3.13

Bellerophon Therapeutics Total Current Assets Related Terms

Thank you for viewing the detailed overview of Bellerophon Therapeutics's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Bellerophon Therapeutics (Bellerophon Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bellerophon Therapeutics Inc (OTCPK:BLPH) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

0HMP:UK

Address

184 Liberty Corner Road, Suite 302, Warren, NJ, USA, 07059

Website

https://www.bellerophon.com

Bellerophon Therapeutics Inc is a clinical-stage therapeutics company. The firm develops innovative products combining novel drugs and devices to treat cardiopulmonary diseases. It develops products under its INOpulse platform, which is an extension of the technology that is used in hospitals to deliver continuous-flow inhaled nitric oxide. The company's products are aimed at the treatment of different kinds of pulmonary hypertension.

Executives

Puissance Life Science Opportunities Fund Vi	10 percent owner	950 THIRD AVENUE, FL 25, NEW YORK NY 10022
Naseem Amin	director	53 FRONTAGE ROAD, SUITE 301, HAMPTON NJ 08827
Mary Ann Cloyd	director	184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059
Theodore T Wang	director	C/O PUISSANCE CAPITAL MANAGEMENT LP, 950 THIRD AVENUE, 25TH FLOOR, NEW YORK NY 10022
Scott P Bruder	director	C/O BELLEROPHON THERAPEUTICS, 53 FRONTAGE ROAD, SUITE 301, HAMPTON NJ 08827
Crispin Teufel	director	184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059
Puissance Capital Fund (gp) Llc	10 percent owner	950 THIRD AVENUE, 25TH FLOOR, NEW YORK NY 10022
Parag Suresh Shah	officer: VP of Business Operations	C/O BELLEROPHON THERAPEUTICS, INC., 184 LIBERTY CORNER ROAD, SUITE 302, NEW JERSEY NJ 07059
Martin Dekker	officer: See Remarks	53 FRONTAGE ROAD, SUITE 301, PERRYVILLE III CORPORATE PARK, HAMPTON NJ 08827
Peter Fernandes	officer: See Remarks	PERRYVILLE III CORPORATE PARK, 53 FRONTAGE ROAD, SUITE 301, HAMPTON NJ 08827
Bobae Kim	officer: VP Reg. Affairs & Quality	184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059
Nicholas Laccona	officer: Controller, (PFO & PAO)	184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059
Steven B Klinsky	10 percent owner	C/O NEW MOUNTAIN CAPITAL, L.L.C., 1633 BROADWAY, 48TH FLOOR, NEW YORK NY 10019
New Mountain Capital, L.l.c.	10 percent owner	1633 BROADWAY, 48TH FLOOR, NEW YORK NY 10019
New Mountain Investments Ii, Llc	10 percent owner	787 SEVENTH AVENUE, 49TH FLOOR, NEW YORK NY 10019